Department of Surgery, Sarcoma Unit, University Medical Center Mannheim (UMM) and Medical Faculty Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany.
German Cancer Research Center (DKFZ), Epidemiological Cancer Registry Baden-Württemberg, Heidelberg, Germany.
J Cancer Res Clin Oncol. 2024 Nov 28;150(12):514. doi: 10.1007/s00432-024-06033-5.
Retroperitoneal sarcomas (RPS) are rare, heterogeneous tumours. Treatment recommendations are mainly derived from cohorts treated at reference centres. The applicability of data from cancer registries (CR) is controversial. This work compares CR and TARPSWG (Transatlantic Australasian Retroperitoneal Sarcoma Working Group) data to assess the representativeness of the TARPSWG and the applicability of the CR data.
TARPSWG cohort has previously been described. The CR Baden-Württemberg cohort includes patients with primary RPS M0 (years 2016-2021, ICD-10 C.49.4/5, C48.x) who underwent surgery within 12 months. Only patients with sarcoma-typical histology codes as used for the German Cancer Society certification system were included. Patient, tumour and therapy factors as well as survival times were compared with Chi-test, Kaplan Meier curves, and adjusted models.
1000 (TARPSWG) and 364 (CR) patients were included. CR patients were older (median: 64 years vs. 58 years), had more high-grade tumours (FNCLCC 3 48.1% vs. 27.4%, p < 0.0001) and the 5-year survival rate was significantly lower (56.3% vs. 67.9%, p = 0.0015). The proportions of dedifferentiated liposarcoma (CR 37.1% vs. 37.0%) and leiomyosarcoma (CR 20.1% vs. 19.2%), and patterns of recurrence in these most frequent RPS subtypes were similar.
ICD-O/ICD 10 based filters appear to be a valid tool for extracting RPS cases from CR. The similar distribution and biological behavior of distinct RPS subtypes suggests that TARPS-WG are representative, and CR data may be used to verify recommendations derived from reference centre cohorts. Complementary use of data from different sources warrants further investigation in rare cancers.
腹膜后肉瘤（RPS）是一种罕见且异质性的肿瘤。治疗建议主要来自于参考中心治疗的队列。癌症登记处（CR）的数据适用性存在争议。本研究比较了 CR 和 TARPSWG（跨大西洋澳大拉西亚腹膜后肉瘤工作组）的数据，以评估 TARPSWG 的代表性和 CR 数据的适用性。
TARPSWG 队列此前已进行描述。CR 巴登-符腾堡队列包括 2016-2021 年间接受手术治疗的 M0 期原发性腹膜后肉瘤患者（ICD-10 C.49.4/5，C48.x），且手术时间在 12 个月内。仅纳入使用德国癌症协会认证系统的肉瘤典型组织学代码的患者。采用卡方检验、Kaplan-Meier 曲线和调整模型比较患者、肿瘤和治疗因素以及生存时间。
共纳入 1000 例（TARPSWG）和 364 例（CR）患者。CR 患者年龄更大（中位数：64 岁 vs. 58 岁），高级别肿瘤比例更高（FNCLCC 3 级 48.1% vs. 27.4%，p<0.0001），5 年生存率显著降低（56.3% vs. 67.9%，p=0.0015）。最常见的 RPS 亚型中去分化脂肪肉瘤（CR 37.1% vs. 37.0%）和 leiomyosarcoma（CR 20.1% vs. 19.2%）的比例以及复发模式相似。
ICD-O/ICD-10 基于的过滤器似乎是从 CR 中提取 RPS 病例的有效工具。不同 RPS 亚型的相似分布和生物学行为表明 TARPS-WG 具有代表性，CR 数据可用于验证来自参考中心队列的建议。不同来源的数据互补使用值得在罕见癌症中进一步研究。
